Testing effectiveness (Phase 2)WithdrawnNCT01854372
What this trial is testing
Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.
Who this might be right for
Newly Diagnosed Diffuse Large B-Cell LymphomaIntermediate (Burkitt-Like) Lymphoma
The University of Texas Health Science Center at San Antonio